Quince Therapeutics (QNCX) retires about $16.4M EIB loan with $5.5M payment
Rhea-AI Filing Summary
Quince Therapeutics, Inc. has eliminated its loan obligations to the European Investment Bank by paying EUR 4,800,000, or approximately $5.5 million, on March 27, 2026. This payment settled outstanding EIB debt of approximately $16.4 million as of that date, and all obligations under the finance and guarantee agreements were fully satisfied and discharged.
The company describes this settlement as a material milestone that removes a significant debt overhang while it continues a corporate restructuring and an evaluation of strategic alternatives, including potential merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Positive
- Quince paid approximately $5.5 million to settle about $16.4 million of EIB debt, significantly reducing obligations for a relatively modest cash outlay.
- The settlement fully discharges obligations under the EIB finance and guarantee agreements, removing a debt overhang as the company pursues restructuring and strategic alternatives.
Negative
- None.
Insights
Quince retired about $16.4M of EIB debt for a $5.5M cash payment, easing its balance sheet during restructuring.
Quince Therapeutics paid EUR 4,800,000 (about $5.5 million) to settle outstanding European Investment Bank obligations of roughly $16.4 million as of March 27, 2026. The finance contract and related guarantee are now fully satisfied and discharged, removing that creditor claim.
This represents a substantial reduction in stated debt for a much smaller cash outlay, which the company characterizes as resolving “critical debt obligations.” Management links the settlement directly to its ongoing restructuring and review of strategic alternatives, such as potential mergers or asset sales, suggesting a cleaner capital structure as it evaluates those options.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02. Termination of a Material Definitive Agreement
As previously disclosed, Quince Therapeutics, Inc. (the “Company”), Quince Therapeutics S.p.A. (the “Borrower”), the European Investment Bank (the “EIB”) and other parties named therein previously entered into a finance contract dated July 24, 2020 (as amended and restated, the “Finance Contract”) and a related guarantee agreement in connection with the Finance Contract (the “Guarantee Agreement,” together with the Finance Contract, the “Finance Documents”).
On March 27, 2026, the Company agreed to pay, on the Borrower’s behalf, EUR 4,800,000, or approximately $5.5 million, to the EIB in full settlement of the Borrower’s obligations under the Finance Documents. As a result of the Company’s payment of such amount, the Company’s and the Borrower’s obligations under the finance documents were deemed satisfied.
Item 7.01. Regulation FD Disclosure
On March 30, 2026, the Company issued a press release announcing the settlement of the Company’s obligations under the Finance Documents. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release issued by Quince Therapeutics, Inc. dated March 30, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Quince Therapeutics, Inc. | ||||||
| By: | /s/ Dirk Thye | |||||
| Date: March 30, 2026 | Name: | Dirk Thye | ||||
| Title: | Chief Executive Officer | |||||
Exhibit 99.1
| NEWS RELEASE |
|
Quince Therapeutics Settles Approximately $16.4 Million of Debt
SOUTH SAN FRANCISCO, Calif. – March 30, 2026 – Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company’s outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value.
Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company’s obligations under both the settlement agreement and the underlying loan agreement have been fully satisfied and discharged.
“The successful completion of the EIB settlement represents a meaningful step forward for Quince as we work to restructure the company and complete an evaluation of strategic alternatives aimed at maximizing shareholder value,” said Dirk Thye, M.D, Quince’s Chief Executive Officer and Chief Medical Officer. “By settling Quince’s debt obligations, we believe that we have removed a substantial overhang that was constraining the company’s flexibility and ability to pursue strategic alternatives, including, but not limited to, merger, reverse merger, asset sale, or other strategic transactions.”
About Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a publicly traded company currently engaged in a corporate restructuring effort as well as an evaluation of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives under consideration may include, but are not limited to, merger, reverse merger, asset sale, or other strategic transactions. For more information on the company and its latest news, visit www.quincetx.com.
Forward-Looking Statements
Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to the company’s evaluation of strategic alternatives, the expected benefits of the EIB loan settlement, and the company’s restructuring activities. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the
611 Gateway Boulevard • Suite 273 • South San Francisco • California • 94080
Quince Therapeutics
Page 2
company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 24, 2025 and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.
Media & Investor Contact:
Brendan Hannah
Quince Therapeutics, Inc.
Chief Operating Officer & Chief Business Officer
ir@quincetx.com